---
title: "Karyopharm Therapeutics Inc. 1Q 2026: Revenue $35.1M, EPS $(1.24) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286411440.md"
description: "Karyopharm Therapeutics Inc. reported Q1 2026 revenue of $35.1M, a 17% increase from Q1 2025, with a narrowed net loss of $22.4M. Diluted EPS improved to $(1.24) from $(2.77) year-over-year. The growth was driven by a 39% rise in U.S. XPOVIO sales and ongoing clinical advancements, including successful Phase 3 trials. The company is expanding its product's global availability and focusing on U.S. commercialization efforts."
datetime: "2026-05-14T11:51:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286411440.md)
  - [en](https://longbridge.com/en/news/286411440.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286411440.md)
---

# Karyopharm Therapeutics Inc. 1Q 2026: Revenue $35.1M, EPS $(1.24) — 10-Q Summary

Karyopharm Therapeutics Inc. reported first-quarter 2026 results with revenue rising to $35.1M and a narrowed net loss of $22.4M versus the year‑ago quarter, driven by stronger U.S. sales of XPOVIO/NEXPOVIO and ongoing clinical progress.

**Financial Highlights**

-   Revenue: $35.1M for Q1 2026, up from $30.0M in Q1 2025 (17% YoY).
-   Net income: Net loss $22.4M for Q1 2026 versus net loss $23.5M in Q1 2025 (loss narrowed by $1.1M, (5%) YoY).
-   Diluted EPS: Diluted net loss per share $(1.24) for Q1 2026 vs $(2.77) in Q1 2025 (improved YoY).

**Business Highlights**

-   Revenue Growth: Net revenue rose 17% YoY to $35.1M, led by a 39% increase in U.S. XPOVIO product sales.
-   Brand Momentum: XPOVIO/NEXPOVIO expanding global approvals and commercial availability across more than 50 territories.
-   Clinical Milestones: SENTRY Phase 3 met its spleen reduction endpoint and showed a topline overall‑survival signal; the company plans FDA engagement.
-   Pipeline Progress: Phase 3 programs XPORT-EC-042 (endometrial cancer) and EMN29 (myeloma) are completed or enrolling, with topline data expected in the second half of 2026.
-   Operational Focus: U.S. commercialization supported by sales forces, nurse liaisons, market access efforts and the KaryForward patient support program.

Original SEC Filing: Karyopharm Therapeutics Inc. \[ KPTI \] - 10-Q - May. 14, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [KPTI.US](https://longbridge.com/en/quote/KPTI.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)

## Related News & Research

- [Karyopharm (KPTI) Leans on SENTRY in Pivotal Call](https://longbridge.com/en/news/287005767.md)
- [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md)
- [Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery](https://longbridge.com/en/news/287100303.md)
- [RBC Capital Remains a Buy on Karyopharm Therapeutics (KPTI)](https://longbridge.com/en/news/286559865.md)
- [Neurothera Labs Announces Adoption of Semi-Annual Reporting](https://longbridge.com/en/news/287119698.md)